All In Biotech

Drug Trial Radar · NCT02239120

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,390

Actual

Start

Nov 27, 2014

Primary completion

Aug 14, 2018

Study completion Aug 14, 2018

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 150 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).

Conditions

  • Stroke
  • Secondary Prevention

Interventions

  • optional ASA as comedicationDrug

    optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

  • placebo to ASADrug

    placebo to comparator drug

  • placebo to optional ASA as comedicationDrug

    optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.

  • placebo to dabigatran etexilateDrug

    placebo

  • ASA 100 mgDrug

    active comparator drug

  • dabigatran etexilateDrug

    active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjudicated Recurrent StrokeTime frame: From randomisation until full follow up period, approximately 43 months.
  2. First Major Bleed (Adjudicated)Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

Locations

569 sites in 42 countries. Site status is shown where the registry gives one.

  • Bronislava Shafran, MD PC

    Phoenix, Arizona

  • Westside Medical Associates of Los Angeles

    Beverly Hills, California

  • TriWest Research Associates, LLC

    El Cajon, California

  • University of California

    Fresno, California

  • Glendale Adventist Medical Center

    Glendale, California

  • Collaborative Neuroscience Network, LLC (CNS)

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Huntington Hospital

    Pasadena, California

  • University of California

    San Diego, California

  • University of California

    San Francisco, California

  • University of Colorado Denver

    Aurora, Colorado

  • Colorado Neurological Institute

    Englewood, Colorado

  • University of Colorado Denver

    Fort Collins, Colorado

  • St. Mary's Hospital and Regional Medical Center

    Grand Junction, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • Boca Raton Regional Hospital

    Boca Raton, Florida

  • Tenet Florida Physician Services

    Boynton Beach, Florida

  • Nova Clinical Research, LLC

    Bradenton, Florida

  • Broward Health North

    Deerfield Beach, Florida

  • Center for Advanced Research Excellence

    Hialeah, Florida

  • Bruce W. Carter, Miami VA Healthcare System

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Bay Neurological Institute

    Panama City, Florida

  • Carol L Pappas, MD PhD PA

    St. Petersburg, Florida

  • University of South Florida

    Tampa, Florida

  • Vero Beach Neurology and Research Institute

    Vero Beach, Florida

  • Palm Beach Neuroscience Institute

    West Palm Beach, Florida

  • Augusta University

    Augusta, Georgia

  • WellStar Medical Group - Neurosurgery

    Marietta, Georgia

  • The Queen's Medical Center

    Honolulu, Hawaii

  • Saint Alphonsus Medical Center-Neurology

    Boise, Idaho

  • Northwest Heart Clinical Research, LLC

    Arlington Heights, Illinois

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Medicoricium, LLC

    Fairview Heights, Illinois

  • OSF Saint Francis Medical Center

    Peoria, Illinois

  • Quincy Physicians and Surgeons Clinic, S.C.

    Quincy, Illinois

Showing 40 of 569 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.